regional cancer therapies - welcome to ccehs · 8:30 am a prognostic model for predicting overall...

For

addi

tion

al in

form

atio

n or

to r

egis

ter

onlin

e, c

onta

ct:

htt

ps:

//cc

ehs.

up

mc.

com

F e b r u a r y 1 4 – 1 6 , 2 0 1 5

Tenth International Symposium on

Regional Cancer TherapiesSheraton Sand Key Resort

Clearwater Beach, Florida

Sponsored by

David C. Koch

Regional Cancer Therapy Center

and

University of Pittsburgh School of Medicine

Center for Continuing Education

in the Health Sciences

and

UPMC Cancer Centers

In Collaboration with

The University of Maryland

Marlene and Stewart Greenebaum

Cancer Center

The Medical College of Wisconsin

Cancer Center

Course Co-Directors

H. Richard Alexander, MD

Professor of Surgery

University of Maryland School of Medicine

Baltimore, Maryland

David L. Bartlett, MD

Professor of Surgery


Pittsburgh, Pennsylvania

Robert P. Edwards, MD

Professor, Obstetrics, Gynecology and

Reproductive Sciences


Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS

Associate Professor of Surgery

Medical College of Wisconsin

Milwaukee, Wisconsin

David

C. K

och

Regi

onal

Canc

er T

hera

py C

ente

r

UPM

C Ca

ncer

Pav

ilion,

Sui

te 4

13

5150

Cen

tre A

venu

e

Pitts

burg

h, P

A 15

232

Nonp

rofit

Org

.U.

S. P

osta

gePA

IDPi

ttsbu

rgh,

PA

Perm

it No

. 383

4

Ten

th I

nte

rnat

ion

al S

ympo

siu

m o

n

Reg

ion

al C

ance

r T

hera

pies

Sher

aton

San

d K

ey R

esor

t, C

lear

wat

er B

each

, Flo

rida

Fe

br

ua

ry

14

–1

6,

20

15

~ 2 ~ ~ 3 ~

Intent and Overview

This course is designed to cover the most recent advances in cancer therapy that are

primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian

and thoracic. Upon completion of the activity, learners from several disciplines should

be able to discuss the latest regional therapies in surgical oncology.

Who Should Attend

This course is designed for physicians and nurses practicing in the areas of Medical,

Surgical, Thoracic, Gynecologic Oncology and Gastroenterology.

Continuing Education Credit

The University of Pittsburgh School of Medicine is accredited by the Accreditation

Council for Continuing Medical Education to provide continuing medical education

for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a

maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only credit

commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 2.0 continuing education units (CEU’s)

which are equal to 20.2 contact hours.

Special Needs

Participation by all individuals is encouraged. Advance notification of any special needs

will help us provide better service. Please notify us of your needs at least two weeks in

advance of the program by calling Maureen Hewko at (412) 623-5993.

We Gratefully Acknowledge Support from:

The Shadyside Hospital Foundation

and

Magee-Womens Research Institute & Foundation

Interactive Audio Response System being used!

Schedule – Saturday, February 14, 2015

6:30 am Registration and Breakfast

6:45 am Welcome

Moderators: Steven Ahrendt, MD, and Konstantinos Votanopoulos, MD

7:00 am The Role of Ki-67 and Preoperative Clinical Parameters to Select

Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients to

Cytoreduction and HIPEC

Shigeki Kusamura, MD, et. al.

7:15 am Clinicopathologic Characteristics and Prognostic Predictors of Survival

in Patients With Signet Ring or Adenocarcinoma of the Appendix

Treated with Cytoreductive Surgery and HIPEC

Chukwuemeka Ihemelandu, MD, et. al.

7:30 am Biologic Factors Associated with Survival in Patients with

Pseudomyxoma Peritonei

Sean Judge, MD, et. al.

7:45 am Diagnostic Laparoscopy is a Safe and Effective Screening Tool for HIPEC

Rebecca Marmor, MD, et. al.

8:00 am Desmoplastic Small Round Cell Tumor: Are all Patients Stage 4?

Andrea Hayes-Jordan, MD, et. al.

8:15 am Outcomes of HIPEC and Cytoreductive Surgery in Young Patients with

Peritoneal Carcinomatosis

Mashaal Dhir, MD, et. al.

8:30 am A Prognostic Model for Predicting Overall Survival in Patients with

Peritoneal Carcinomatosis of an Appendiceal Origin Treated with

Cytoreductive Surgery and HIPEC

Chukwuemeka Ihemelandu, MD, et. al.

8:45 am Knowledge, Attitudes, and Practice of HIPEC Surgeons Regarding

Nutrition Support

George Salti, MD, et. al.

9:00 am Impact of Major Complications on Patients’ Quality of Life After

Cytoreductive Surgery and HIPEC

Trevor Hamilton, MD, et. al.

~ 4 ~ ~ 5 ~

9:15 am Cytoreductive Surgery and HIPEC for Patients with

Hepatocellular Carcinoma

Aviram Nissan, MD, et. al.

9:30 am DEBATE:

HIPEC is an Accepted Approach for Sarcomatosis

PRO: Lana Bijelic, MD — CON: Kiran Turaga, MD

10:00 am Break/Exhibitors/Posters

Moderators: Robert Edwards, MD, and Marcello Deraco, MD

10:15 am Risk Stratification and Selection of Patients for Cytoreductive Surgery

and HIPEC According to Risk of Procedure Related Mortality

Shigeki Kusamura, MD, et. al.

10:30 am Age-Related Morbidity and Mortality with Cytoreductive Surgery and

Intraperitoneal Chemotherapy: An ACS NSQIP Database Review

Madalyn Peters, MD, et. al.

10:45 am Stoma Creation and Reversal after Cytoreductive Surgery with HIPEC

Andrea Doud, MD, et. al.

11:00 am The American Society of Peritoneal Surface Malignancies (ASPSM)

Multi-Institution Evaluation of 773 Patients with Epithelial Ovarian

Cancer with Peritoneal Metastases

Jesus Esquivel, MD, et. al.

11:15 am Systemic Hyperthermia Delivered as Hyperthermic Extracorporeal

Applied Tumor Therapy (HEATT), for Recurrent Ovarian Cancer:

Case Report of Safe Delivery of Six Cycles

Roger Vertrees, PhD, et. al.

11:30 am HIPEC Outcomes in Ovarian Epithelial Cancer at Index Surgery,

Salvage and Palliative CRS/HIPEC

Duncan Watley, MD, et. al.

11:45 am Cytoreductive Surgery with HIPEC is a Therapeutic Option for Patients

with Uterine Leiomysarcoma after Hysterectomy and Morcellation

Lana Bijelic, MD, et. al.

Noon GUEST LECTURER

Novel Intraperitoneal Immunotherapy Approaches to Ovarian Cancer

Ronald Alvarez, MD

12:30 pm Break for Lunch

12:45 pm CONTROVERSIAL CASE DISCUSSIONS

Moderator: H. Richard Alexander, MD Case Discussants: Edward Levine, MD, Daniel Labow, MD, and John Kane III, MD, Jesus Esquivel, MD, and Brian Loggie, MD

Rapid Recurrence of Low-Grade Mucinous Appendiceal Neoplasm —

Chemotherapy or Reoperation or Observation?

Completely Resected Ruptured Mucinous Appendiceal Neoplasm

(Low-Grade) — Observation or Reoperation?

High-Volume Colorectal Cancer with Good Response to Chemotherapy,

but Persistent High PCI — Is CRS/HIPEC Ever an Option?

Low-Volume, High-Grade Peritoneal Mesothelioma — Chemotherapy

or Cytoreductive Surgery Plus HIPEC?

1:30 pm Saturday Session Adjournment

6:00 pm Poster Sessions

7:00 pm MEET THE PROFESSOR RECEPTION

Presentation of Gabriella Graham Patient Advocate Award

Schedule — Sunday, February 15, 2015


6:45 am Welcome

Moderators: T. Clark Gamblin, MD, MS, and James Pingpank Jr., MD

7:00 am Comparative Effectiveness of Hepatic Artery Based Therapies for

Unresectable Intrahepatic Cholangiocarcinoma

Thejus Jayakrishnan, MD, et. al.

7:15 am Long Term Follow-up of Isolated Hepatic Perfusion for Uveal Melanoma

Liver Metastases

Roger Olofsson Bagge, MD, et. al.

7:30 am Safety and Efficacy of Transarterial Chemoembolization in Patients

with Transjugular Intrahepatic Portosystemic Shunts

John Miura, MD, et. al.

~ 6 ~ ~ 7 ~

7:45 am A Single Institutions Experience with Percutaneous Hepatic Perfusion

for Unresectable Melanoma or Sarcoma to the Liver

Omar Rashid, MD, et. al.

8:00 am TACE for Metastatic NET with Massive Hepatic Tumor Burden:

Is the Benefit Worth The Risk?

Mio Kitano, MD, et. al.

8:15 am Treatment of Metastatic Neuroendocrine Tumors (NET) with Transarterial

Chemoembolization Using Doxorubicin-Eluting Beads (DEBDOX)

Mura Assifi, MD, et. al.

8:30 am GUEST LECTURER

Update on Liver-Directed Therapies for Hepatic Malignancy

Michael Soulen, MD


Moderators: Douglas Tyler, MD, and Jonathan Zager, MD

9:30 am Overall Survival (OS) Analysis from a Randomized Phase 3 Trial of

Talimogene Laherparepvec (T-VEC) versus Subcutaneous Granulocyte-

Macrophage Colony Stimulating Factor (GM-CSF) in Patients with

Unresectable Regional Melanoma Metastases

Howard Kaufman, MD, et. al.

9:45 am Induction of Anti-Melanoma Immunity After Intralesional

Ablative Therapy

Amod A. Sarnaik, MD, et. al.

10:00 am 3D CT for Accurate Isolated Regional Therapy Limb Volume Calculation

Rebecca Tuttle, MD, et. al.

10:15 am Lymph Node Ratio is an Important Prognostic Factor in Melanoma

Alessandro Testori, MD, et. al.

10:30 am Systemic Anti-Tumor Effects Associated with Ipilimumab

Preconditioning and Isolated Limb Perfusion

Minhyung Kim, MD, et. al.

10:45 am Melphalan ILI Can Produce an Abscopal Effect in the Presence of

Systemic Checkpoint Blockade

Masahito Tsutsui, MD, et. al.

11:00 am Exploring Doxorubicin as a Mediator of Immunogenic Cell Death

in a Regional Chemotherapy Immune Competent Murine Model

of Advanced Extremity Melanoma

Masahito Tsutsui, MD, et. al.


Moderators: Matthew Holtzman, MD, and Glen Balch, MD

11:30 am The Learning Curve of Cytoreductive Surgery and HIPEC:

Analysis of 324 Procedures in a Tertiary Center

Wenceslao Vasquez-Jimenez, MD, et. al.

11:45 am Perioperative Outcomes after HIPEC for Gastric Peritoneal Carcinomatosis

Audrey Choi, MD, et. al.

Noon Extreme Cytoreductive Surgery and HIPEC: Outcomes from a Single

Tertiary Institution

Yaniv Berger, MD, et. al.

12:15 pm Mexican National Effort to Integrate Cytoreductive Surgery and HIPEC

into the Management of Gastrointestinal and Gynecologic Cancer

Guillermo Flores Ayala, MD, et. al.

12:30 pm GUEST LECTURER

Theoretical Considerations for an Optimal CRS and HIPEC

Paul Sugarbaker, MD

1:00 pm Break for Lunch

1:15 pm Best of PSOGI, International Congress on Peritoneal

Surface Malignancies

David L. Bartlett, MD

1:45 pm Sunday Session Adjournment

6:00 pm Poster Viewing

7:00 pm ASPSM Meeting

~ 8 ~ ~ 9 ~

Schedule – Monday, February 16, 2015


6:45 am Welcome

Moderators: Haroon Choudry, MD and Joseph Skitzki, MD

7:00 am Clinical Outcome, Genomic Profile Analysis and Possible Therapeutic

Options in 11 Patients with Mucinous Appendiceal Neoplasms Treated

with Cytoreductive Surgery and HIPEC

Jesus Esquivel, MD, et. al.

7:15 am Radiovirotherapy of Colorectal Peritoneal Carcinomatosis Using a

Somatostatin Receptor-Expressing Oncolytic Virus Combined with

177-Lu-DOTATOC

J. Andrea McCart, MD, et. al.

7:30 am Proposal for a Renewed Cancer Index (PCI) and Completeness of

Cytoreduction (CC) Scores Evaluation Based on Tridimensional

Integrated Sharable Digital Tool

Paolo Sammartino, MD, et. al.

7:45 am Malignant Peritoneal Mesothelioma: Characterization of Inflammatory

Response within the Peritoneal Microenvironment

Sean Judge, MD, et. al.

8:00 am HIPEC and IP Treatment in Peritoneal Malignancies

Gleneara Bates, MD, et. al.

8:15 am Early Identification of DPAM in “At Risk” MAN Patients —

A New Approach to MAN Surveillance

Jason Foster, MD, et. al.

8:30 am Impact of Restricted Fluid Administration During Cytoreductive

Surgery and Hyperthermic Intraperitoneal Chemoperfusion on

Perioperative Outcomes

James Padussis, MD, et. al.

8:45 am Conditional Survival as a Patient Centered Metric for Patients with

Appendiceal Adenocarcinoma

Kiran Turaga, MD, et. al.

9:00 am GUEST LECTURER

A Core Microbiome Associated with the Peritoneal Tumors of PMP

D. Scott Merrell, PhD


Moderators: James Cusack, MD, and Garrett Nash, MD

10:00 am Promoting Entry into Clinical Trials and Improving Access to

Specialist Treatment and Care

Mary Hessdorffer, NP

10:15 am Effects of HIPEC on Peritoneal Metastases Developed from Gastric Cancer

Yutaka Yonemura, MD, et. al.

10:30 am Matched Case-Control Study of HIPEC for the Prevention and Early

Treatment of Colorectal Cancer Peritoneal Metastases

Dario Baratti, MD, et. al.

10:45 am Adjuvant HIPEC for Patients with High-Risk Peritoneal-Based

Malignancies: Who Benefits and How Much?

Jeffrey Sussman, MD, et. al.

11:00 am Conditional Survival After Cytoreductive Surgery with HIPEC for Low and

High Grade Appendiceal Primaries

Harveshp Mogal, MD, et. al.

11:15 am Malignant Peritoneal Mesothelioma: Incorporation of a Novel

Pathologic Grading into a Recently Proposed tnm Classification

Improves Outcome Prediction

Dario Baratti, MD, et. al.

11:30 am Cytoreductive Surgery and HIPEC in Patients with Liver Involvement

Yaniv Berger, MD, et. al.

11:45 am Safety and Efficacy of Concurrent Surgical Therapy for Peritoneal

Carcinomatosis and Synchronous Hepatic Metastases in Patients with

Disseminated Colorectal Cancer

Stephanie Downs-Canner, MD, et. al.

~ 10 ~ ~ 11 ~

Noon INTERESTING CASE PRESENTATIONS

Moderator: Charles Staley, MD

Cytoreductive Surgery and HIPEC for Fibrolamellar Hepatocellular

Carcinoma with Carcinomatosis

Nathan Hinkle, MD, et. al.

Pseudomyxoma Peritonei from a Borderline Mucinous Tumor Arising

in an Ovarian Mature Cystic Teratoma

Amareshwar Chiruvella, et. al.

Recurrence of Peritoneal Mesothelioma (originally epitheliod) as a

Rapidly Enlarging Mass of Malignant Mesothelioma

Michael D. Kluger, MD

Complete Pathologic Response Found at the Time of CRS and HIPEC

for PC from Rectal Cancer

Rajesh Nair, MD

Gastric Cancer Carcinomatosis

Joseph Kim, MD

Desmoplastic Small Round Cell Tumor of the Peritoneal Cavity in a

31-Year-Old Male

James Cusack, MD

1:00 pm Announcement and Presentation of Poster Award Winners

1:15 pm Break for Lunch and Conference Adjournment

Poster Presentations

1. Quality of Life after Isolated Limb Perfusion for In-Transit Metastases of Malignant

Melanoma. Roger Olofsson Bagge, MD, et. al.

2. Correlation of Morbidity, PCI and Survival , after HIPEC. Horacio Lopez-Basave, MD, et. al.

3. Pharmacologic Studies in the Use of Nanoparticles in Perioperative Chemotherapy

with Pegylated Liposomal Doxorubicin. Paul H. Sugarbaker, MD, et. al.

4. Peritoneal Metastases from Mucinous Endocervical Adenocarcinoma.

Paul H. Sugarbaker, MD, et. al.

5. Peritoneal Metastases Observed in Follow-Up After Robotic Cancer Resections

May be Distributed by Gravitational Forces. Paul H. Sugarbaker, MD, et. al.

6. HIPEC for Epithelial Ovarian Cancers: Is There a Role? Michelle Boisen, MD, et. al.

7. Monitoring Intraperitoneal (IP) Port Cytology After IP Chemotherapy for Ovarian

Cancer: A Predictor of Outcome? Maryann Kwa, MD, et. al.

8. Isolated Limb Infusion in a Pregnant Patient with Sarcoma of the Upper Limb:

Case Report. Vladimir Milovanov, MD, et. al.

9. Isolated Limb Infusion: A Single Center Experience. Vadim Gushchin, MD, et. al.

10. Oncologic Outcomes Following Repeat Cytoreductive Surgery with HIPEC for

Disseminated Peritoneal Carcinomatosis. Filip Bednar, MD, et. al.

11. Serum Cytokine Levels after Isolated Limb Infusion and Ipilimumab in the

Treatment of Malignant Melanoma. Jamie Green, MD, et. al.

12. Cytoreductive Surgery and HIPEC: Alternative Treatment in Patients with

Peritoneal Carcinomatosis from Small Bowel Neuroendocrine Tumors.

Maria Fernanda Nunez, MD, et. al.

13. The ASPSM Multi-Institution Evaluation of Laparoscopic Cytoreductive Surgery

and HIPEC. Jesus Esquivel, MD, et. al.

14. Biologic Factors Associated with Survival in Patients with Pseudomyxoma

Peritonei. Sean Judge, MD, et. al.

15. Prophylactic HIPEC in Patients with Appendiceal Neoplasms: A Case Series.

Daniel Tuvin, MD, et. al.

The University of Pittsburgh is an affirmative action, equal opportunity institution.

~ 12 ~ ~ 13 ~

16. Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial

Non-Definitive Surgical Intervention in Patients with Peritoneal Carcinomatosis

of a Colorectal Origin. Chukwuemeka Ihemelandu, MD, et. al.

17. Cross-Sectional Imaging of Peritoneal Carcinomatosis: Systemic Review and

Meta-Analysis. Franco Iafrate, MD, et. al.

18. Safety and Outcomes of Cytoreductive Surgery and HIPEC in Elderly Patients with

High PCI Large Volume Peritoneal Metastasis. Richard Sleightholm, MD, et. al.

19. Safety and Efficacy of Cytoreductive Surgery and HIPEC in Elderly Patients.

Patricio Polanco, MD, et. al.

20. Neoadjuvant Chemotherapy with Bevacizumab Does Not Affect Complications in

Patients with Peritoneal Carcinomatosis From Colorectal Cancer Treated by

Cytoreduction and HIPEC. Wenceslao Vasquez-Jimenez, MD, et. al.

21. Evaluation of HIPEC Charges and Payments at a Community Hospital.

Cristina O’Donoghue, MD, et. al.

22. Routine Admission to ICU After Cytoreductive Surgery (CRS) and HIPEC:

Not Always a Requirement. Chukwuemeka Obiora, MD, et. al.

23. Outcomes and Histopathologic Correlation According to Age in Patients with

Appendiceal Neoplasms After Cytoreductive Surgery with HIPEC. Maria Fernanda

Nunez, MD, et. al.

24. Peritoneal Carcinomatosis with Goblet Cell Features: Outcomes from a Single

Large Institution. Michal Radomski, MD, et. al.

25. Respiratory Function and Functional Capacity of Patients with Peritoneal

Metastases and Candidates to Cytoreductive Surgery and Perioperative

Chemotherapy. Vinicius Gava, MD, et. al.

26. Defining the Safety of Epidural Pain Control in CRS/HIPEC in Conjunction with VTE

Prophylaxis. Richard Sleightholm, MD, et. al.

27. Isolated Chemotherapeutic Perfusion as Neoadjuvant Therapy for Advanced/

Unresectable Pelvic Malignancy. Harold Wanebo, MD.

Course Co-Directors

H. Richard Alexander, MDProfessor of Surgery

University of Maryland School of Medicine

Baltimore, MD

David L. Bartlett, MDProfessor of Surgery


Robert P. Edwards, MDProfessor, Obstetrics, Gynecology and

Reproductive Sciences


T. Clark Gamblin, MD, MSStuart D. Wilson Chair in Surgical Oncology

Chief, Division of Surgical Oncology



Milwaukee, WI

Invited Faculty

Steven Ahrendt, MDAssociate Professor of Surgery


Ronald Alvarez, MDProfessor, Division of Gynecologic Oncology

University of Alabama at Birmingham

Birmingham, AL

Glen Balch, MDAssistant Professor of Surgery

University of Texas

Southwestern Medical Center

Dallas, TX

Lana Bijelic, MDMedstar Washington Hospital Center

Washington, DC

Haroon Choudry, MDAssistant Professor of Surgery


James Cusack, MDAssociate Professor of Surgery

Harvard Medical School

Boston, MA

Marcello Deraco, MDSurgical Oncologist

Fondazione IRCCS Instituto

Nazionale dei Tumori

Milan, Italy

Jesus Esquivel, MDMedical Direction, International

Oncology Initiatives

CTCA

Philadelphia, PA

Jason Foster, MDAssociate Professor of Surgery

Nebraska Medical Center

Omaha, NE

Andrea Hayes-Jordan, MDAssistant Professor of Pediatric Surgery

University of Texas MD Anderson

Cancer Center

Houston, TX

Mary Hesdorffer, NPExecutive Director

Mesothelioma Applied Research Foundation

Alexandria, VA

Matthew Holtzman, MDAssociate Professor of Surgery


John Kane III, MDAssociate Professor of Oncology

Roswell Park Cancer Institute


University of Buffalo

Buffalo, NY

Joseph Kim, MDAssociate Professor of Surgery

City of Hope National Medical Center

Duarte, CA

~ 14 ~ ~ 15 ~

Michael Kluger, MDAssistant Professor of Surgery

New York-Presbyterian Hospital

New York, NY

Daniel Labow, MDAssociate Professor

Mt. Sinai School of Medicine

New York, NY

Edward Levine, MDProfessor of Surgery

Wake Forest University

Winston-Salem, NC

Brian Loggie, MDProfessor of Surgery

Creighton University Medical Center

Omaha, NE

J. Andrea McCart, MDAssistant Professor

University of Toronto

Toronto, Canada

D. Scott Merrell, PhDProfessor

Uniformed Services University

Bethesda, MD

Rajesh Nair, MDAssistant Professor of Surgery

University of Florida

Orlando, FL

Garrett Nash, MDAssistant Attending Surgeon, MSKCC

Assistant Professor of Surgery

Weill-Cornell Medical College

New York, NY

James Pingpank Jr., MDAssociate Professor of Surgery


Joseph Skitzki, MDAssistant Professor

Roswell Park Cancer Institute and

State University of New York

Buffalo, NY

Michael Soulen, MDProfessor of Radiology and Surgery

Director of Interventional Oncology

Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA

Charles Staley, MDProfessor of Surgery

Emory University

Atlanta, GA

Paul H. Sugarbaker, MDDirector, Program in Peritoneal

Surface Malignancy

Washington Hospital Centre

Washington, DC

Kiran Turaga, MDAssistant Professor of Surgery


Milwaukee, WI

Douglas S. Tyler, MDProfessor of Surgery

Duke University

Durham, NC

Konstantinos Votanopoulos, MDAssistant Professor of Surgery

Wake Forest University

Winston-Salem, NC

Jonathan Zager, MDAssociate Professor of Surgery

Moffitt Cancer Center

Tampa, FL

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.

Abstract/Poster Presenters

Mura Assifi, MD


Pittsburgh, PA

Guillermo Flores Ayala, MD

Instituto Jaliscience de Cancerología

Guadalajara, Mexico

Roger Olofsson Bagge, MD

Sahlgrenska University Hospital

Gothenburg, Sweden

Dario Baratti, MD

Instituto Nazionale Tumori

Milan, Italy

Horacio Lopez Basave, MD

Instituto Nacional de Cancerología de

Mexico

Mexico City, Mexico

Gleneara Bates, MD

Columbia University Medical Center

New York, NY

Filip Bednar, MD


Pittsburgh, PA

Yaniv Berger, MD

Mount Sinai Medical Center

New York, NY

Michelle Boisen, MD

Magee-Womens Hospital of UPMC

Pittsburgh, PA

Amareshwar Chiruvella, MD

Emory Medical Center

Atlanta, GA

Audrey Choi, MD

City of Hope National Medical Center

Duarte, CA

Mashaal Dhir, MD


Pittsburgh, PA

Andrea Doud, MD

Wake Forest University Department of

General Surgery

Winston-Salem, NC

Stephanie Downs-Canner, MD


Pittsburgh, PA

Vinicius Gava, MD

Hospital Moinhos de Vento

Porto Alegre, RS, Brazil

Jamie Green, MD

Memorial Sloan Kettering Cancer Center

New York, NY

Vadim Gushchin, MD

Mercy Medical Center

Baltimore, MD

Trevor Hamilton, MD

Mt. Sinai Hospital

Toronto, Canada

Nathan Hinkle, MD

University of Tennessee Health

Sciences Center

Memphis, TN

Franco Iafrate, MD

Sapienza University of Rome

Rome, Italy

~ 16 ~ ~ 17 ~

Chukwuemeka Ihemelandu, MD

MedStar Washington Hospital Center

Washington, DC

Thejus Jayakrishnan, MD


Milwaukee, WI

Sean Judge, MD

Creighton University School of Medicine

Omaha, NE

Howard Kaufman, MD

Rutgers Cancer Institute of New Jersey

New Brunswick, NJ

Minhyung Kim, MD


Buffalo, NY

Mio Kitano, MD

The Hospital State University

Columbus, OH

Shigeki Kusamura, MD

Milan Tumor Institute

Milan, Italy

Maryann Kwa, MD

New York University Cancer Institute

New York, NY

Rebecca Marmor, MD

Moores Cancer Center

San Diego, CA

Vladimir Milovanov, MD


Baltimore, MD

John Miura, MD


Milwaukee, WI

Harveshp Mogal, MD

Wake Forest School of Medicine

Winston-Salem, NC

Aviram Nissan, MD

Kyriat Hadassah

Jerusalem, Israel

Maria Fernanda Nunez, MD


Baltimore, MD

Chukwuemeka Obiora, MD

Wake Forest Baptist Medical Center

Winston-Salem, NC

Cristina O’Donoghue, MD

University of Illinois at Chicago and

Edward Cancer Center

Naperville, IL

James Padussis, MD


Pittsburgh, PA

Madalyn Peters, MD

Hospital of the University of Pennsylvania

Philadelphia, PA

Patricio Polanco, MD

UT Southwestern

Dallas, TX

Michal Radomski, MD


Pittsburgh, PA

Omar Rashid, MD

H. Lee Moffitt Cancer Center

Tampa, FL

George Salti, MD

Edward Hospital Cancer Center/

University of Illinois at Chicago

Naperville, IL

Paolo Sammartino, MD

Sapienza University of Rome

Rome, Italy

Amod Sarnaik, MD

H. Lee Moffitt Cancer Center

Tampa, FL

Richard Sleightholm, MD


Omaha, NE

Jeffrey Sussman, MD

University of Cincinnati

Cincinnati, OH

Alessandro Testori, MD

Chairman of Melanoma Group

Milan, Italy

Masahito Tsutsui, MD

Duke University

Durham, NC

Rebecca Tuttle, MD


Buffalo, NY

Daniel Tuvin, MD

Mount Sinai Medical Center

New York, NY

Wenceslao Vasquez-Jimenez, MD

Hospital General Universitario

Gregorio Maranon

Madrid, Spain

Roger Vertrees, PhD

Verthermia, Inc.

San Jose, CA

Harold Wanebo, MD

Landmark Medical Center

Woonsocket, RI

Duncan Watley, MD


Omaha, NE

Yutaka Yonemura, MD

Kishiwada Tokushukai Hospital

Osaka, Japan

~ 18 ~

Registration Information

Online Registration is accepted until February 13, 2015. After this date, you are only

able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS

conferences.

Visit our online registration site at https://ccehs.upmc.com. Scroll down to the Tenth

International Symposium on Regional Cancer Therapies section on the web page.

• Click the registration button and enter all of the requested information.

• After registering, an electronic confirmation will be sent to the email address you

provided when you registered.

Registration is not complete until you receive the confirmation email for your

preregistration. If you do not receive this letter within 5-7 days of registration, please

contact Maureen Hewko at (412) 623-5993.

You must bring this confirmation with you to the conference.

Registration Cancellation

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition

cancellations postmarked or date stamped before January 15, 2015 will be completely

refunded. After January 15, 2015, a $35 administrative fee will be assessed. No refunds

will be made after February 1, 2015.

Conference contact for cancellation requests:

Maureen Hewko, MBA

UPMC Cancer Pavilion 413, 5150 Centre Avenue

Pittsburgh, PA 15232

Email: [email protected] • Telephone: (412) 623-5993

Fax: (412) 692-2520

Registration Fees

$300 Physicians and researchers

$200 Nurses and other health care professionals

Registration fee includes:

• Continuing education credit

• Registration and course materials

• Continental breakfast, refreshments and a light lunch

Meeting Location

The conference will be held at the Sheraton Sand Key Resort. Conference reservations are at the sole responsibility of the attendees who may contact the hotel. If registering for a room at the hotel online, please go to http://www.regionaltherapies.com and click on conference information.

If you wish to make your reservation by phone, please call 1-727-595-1611 and refer to code UPMC15.

The cut-off date for reserving a room at the discounted rate of $205 per night is January 15, 2015.

Accommodations

Nightly Guest Room Rate: $205 per night

Note: Resorts room rates are subject to additional taxes and resort fees as applicable.

Transportation

For up-to-date transportation information, go to the Koch Center Website:

http://www.regionaltherapies.com

If you are flying to the conference, the closest airport to the Sheraton is the Tampa International Airport.

For additional information, contact:

Maureen Hewko, MBATelephone: (412) 623-5993Fax: (412) 692-2520Email: [email protected] Center Website: http://www.regionaltherapies.com

Visit the Center for Continuing Education in the Health Sciences Web Site

Our Internet address is: https://ccehs.upmc.com

The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs.

regional cancer therapies - welcome to ccehs · 8:30 am a prognostic model for predicting overall...

Documents